Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,985 active trials259 approved drugs4,032 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06563934 | Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs) | not yet recruiting | Phase 2 | 70 | Xu Yong, MDOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06321016 | POZIKIDS: Exercise and Comprehensive Care to Improve the Quality of Life of Children and Adolescents With Cancer(PoziKids) | not yet recruiting | N/A | 45 | Nere MendizabalOTHER_GOV | 0 | Aug 20, 2024 | clinicaltrials |
| NCT06561646 | To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer | not yet recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06524219 | Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery. | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 19, 2024 | clinicaltrials |
| NCT06557954 | Cervical Cytology DNA Methylation for Cervical Cancer Screening | not yet recruiting | — | 30,000 | Lei LiOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06559644 | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | not yet recruiting | Early Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06557096 | CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC | not yet recruiting | Early Phase 1 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06557213 | a Cohort Study (Gut Microbiota and HCC) | not yet recruiting | — | 100 | Xu Yong, MDOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06558019 | Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence | not yet recruiting | — | 509 | Lei LiOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06558175 | Reirradiation Dose Escalation in Thoracic Cancers(REPAIR) | not yet recruiting | Phase 1 | 48 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06554535 | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Aug 15, 2024 | clinicaltrials |
| NCT06556186 | Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma | not yet recruiting | N/A | 600 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Aug 15, 2024 | clinicaltrials |
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06553781 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma | not yet recruiting | N/A | 28 | Fudan UniversityOTHER | 0 | Aug 14, 2024 | clinicaltrials |
| NCT06554028 | Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer | not yet recruiting | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05628610 | Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer | not yet recruiting | Phase 2 | 130 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 13, 2024 | clinicaltrials |
| NCT06550765 | Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors | not yet recruiting | N/A | 98 | Guangdong Provincial People's HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06551896 | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
| NCT06548178 | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | not yet recruiting | Phase 2 | 242 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06548438 | The Impact of PDD During TURB for NMIBC(TUR_BLUE) | not yet recruiting | Phase 4 | 300 | A.O.U. Città della Salute e della ScienzaOTHER | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06547476 | Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed | not yet recruiting | Phase 2 | 40 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06364501 | Phase 1 Trial of KH801 | not yet recruiting | Phase 1 | 17 | Beijing Kanghong Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06524778 | Single High-dose Brachytherapy for Giant Osteosarcoma Masses | not yet recruiting | Phase 2 | 16 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06541171 | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results(FOFU) | not yet recruiting | — | 220 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06541288 | A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer | not yet recruiting | N/A | 230 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06090513 | Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients | not yet recruiting | — | 300 | Bien-Willner Physicians Group PAOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06538935 | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06537505 | A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors | not yet recruiting | Phase 2 | 60 | Beidahuang Industry Group General HospitalOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT06535737 | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab(CPAB) | not yet recruiting | Phase 2 | 40 | Chulalongkorn UniversityOTHER | 0 | Aug 2, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05474859 | Subjects With Advanced or Metastatic Solid Tumor Malignancies | not yet recruiting | Phase 1 | 30 | Xenthera, Inc.INDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06276803 | The LINFU® U.S. Registry for the in the General Population Without Risk Factors | not yet recruiting | — | 500 | Adenocyte, LLCINDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06525714 | Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 302 | The First Hospital of Jilin UniversityOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06530082 | A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer | not yet recruiting | Phase 1 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06530524 | Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery | not yet recruiting | Phase 2 | 50 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530810 | Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) | not yet recruiting | Phase 1 | 100 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06526624 | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 406 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06526897 | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | not yet recruiting | N/A | 1,582 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06528223 | Research of the Application of Artificial Intelligence Model "PANDA" | not yet recruiting | N/A | 200,000 | Zhejiang UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06528236 | Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass | not yet recruiting | — | 100,000 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 30, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 21, 2024source: clinicaltrials